Enhanc3D Genomics raises £10 million in Series A financing to advance GenLink3D proprietary technology platform
Cambridge, UK, 20th October 2022: Enhanc3D Genomics (“Enhanc3D”), a functional genomics company unlocking the full potential of the human 3D genome to transform therapeutic development, today announces it has raised £10 million in Series A financing to accelerate the development of its proprietary technology platform – “GenLink3DTM”. The financing was led by BGF and Parkwalk Advisors, with support from existing private investors and Bioqube Ventures.
